Buni Maryam, Joseph Joyce, Pedroza Claudia, Theodore Sam, Nair Deepthi, McNearney Terry A, Draeger Hilda T, Reveille John D, Assassi Shervin, Mayes Maureen D
From the Department of Internal Medicine, Center for Clinical Research and Evidence-Based Medicine, and Department of Pediatrics, University of Texas McGovern Medical School, Houston, Texas, USA.
M. Buni, MD, Rheumatology Fellow, McGovern Medical School; J. Joseph, MD, Washington DC VA Medical Center; C. Pedroza, PhD, Associate Professor, McGovern Medical School; S. Theodore, MD, Research Coordinator I, McGovern Medical School; D. Nair, MS, Data Manager Contractor; T.A. McNearney, MD; H.T. Draeger, MD, University Health System - University Medicine Associates; J.D. Reveille, MD, Professor, McGovern Medical School; S. Assassi, MD, Associate Professor, McGovern Medical School; M.D. Mayes, MD, Professor, McGovern Medical School. Dr. Buni and Dr. Joseph contributed equally to this paper and are co-first authors.
J Rheumatol. 2019 Dec;46(12):1597-1604. doi: 10.3899/jrheum.180093. Epub 2019 Feb 1.
To identify baseline features that predict progression of hand contractures and to assess the effect of contractures on functional status in the prospective GENISOS cohort.
Rate of decline in hand extension, as an indicator of hand contracture, was the primary outcome. We assessed longitudinal hand extension measurements, modified Health Assessment Questionnaire (MHAQ) score, Medical Outcomes Study Short Form-36 (SF-36) physical function score, and demographic, clinical, and serological variables. Subjects with ≥ 2 hand measurements at least 6 months apart were included.
A total of 1087 hand measurements for 219 patients were available over an average of 8.1 ± 4.8 years. Hand extension decreased on average by 0.11 cm/year. Antitopoisomerase I antibody (ATA) positivity and higher modified Rodnan Skin Score (mRSS) were predictive of faster decline in hand extension (p = 0.009 and p = 0.046, respectively). In a subgroup analysis of 62 patients with ≤ 2 years from SSc onset, ATA and diffuse disease type were associated with faster decline in hand extension; anticentromere positivity was associated with slower rate of decline. Although the rate of decline in patients with disease duration ≤ 2 years was numerically higher, the difference was not statistically significant. Hand extension continued to decline in a linear fashion over time and was inversely related to overall functional status.
ATA was predictive of contracture development in both early disease (≤ 2 yrs) and in the overall cohort. Hand extension declined linearly over time and was inversely associated with MHAQ and SF-36 scores. ATA positivity and higher baseline mRSS were predictive of faster decline in hand extension.
在前瞻性GENISOS队列中确定可预测手部挛缩进展的基线特征,并评估挛缩对功能状态的影响。
作为手部挛缩指标的手部伸展度下降率是主要结局。我们评估了纵向手部伸展度测量值、改良健康评估问卷(MHAQ)评分、医学结局研究简明健康调查36项量表(SF-36)身体功能评分以及人口统计学、临床和血清学变量。纳入相隔至少6个月有≥2次手部测量的受试者。
在平均8.1±4.8年的时间里,共获得了219例患者的1087次手部测量数据。手部伸展度平均每年下降0.11厘米。抗拓扑异构酶I抗体(ATA)阳性和较高的改良罗德南皮肤评分(mRSS)可预测手部伸展度下降更快(分别为p = 0.009和p = 0.046)。在发病≤2年的62例患者的亚组分析中,ATA和弥漫型疾病与手部伸展度下降更快相关;抗着丝点抗体阳性与下降速率较慢相关。虽然病程≤2年的患者下降速率在数值上更高,但差异无统计学意义。手部伸展度随时间呈线性持续下降,且与整体功能状态呈负相关。
ATA在疾病早期(≤2年)和整个队列中均能预测挛缩的发展。手部伸展度随时间呈线性下降,且与MHAQ和SF-36评分呈负相关。ATA阳性和较高的基线mRSS可预测手部伸展度下降更快。